{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:09:05Z","timestamp":1793862545338,"version":"4.6.1"},"reference-count":171,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The success of the first licensed mRNA-based vaccines against COVID-19 has created a widespread interest on mRNA technology for vaccinology. As expected, the number of mRNA vaccines in preclinical and clinical development increased exponentially since 2020, including numerous improvements in mRNA formulation design, delivery methods and manufacturing processes. However, the technology faces challenges such as the cost of raw materials, the lack of standardization, and delivery optimization. MRNA technology may provide a solution to some of the emerging infectious diseases as well as the deadliest hard-to-treat infectious diseases malaria, tuberculosis, and human immunodeficiency virus\/acquired immunodeficiency syndrome (HIV\/AIDS), for which an effective vaccine, easily deployable to endemic areas is urgently needed. In this review, we discuss the functional structure, design, manufacturing processes and delivery methods of mRNA vaccines. We provide an up-to-date overview of the preclinical and clinical development of mRNA vaccines against infectious diseases, and discuss the immunogenicity, efficacy and correlates of protection of mRNA vaccines, with particular focus on research and development of mRNA vaccines against malaria, tuberculosis and HIV.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1172691","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T04:27:07Z","timestamp":1682310427000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":62,"title":["mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV"],"prefix":"10.3389","volume":"14","author":[{"given":"Laura","family":"Matarazzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo J. G.","family":"Bettencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1038\/nm1209","article-title":"Vaccines: past, present and future","volume":"11","author":"Plotkin","year":"2005","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2016.05.004","article-title":"Childhood vaccination: Implications for global and domestic public health","volume":"34","author":"Younger","year":"2016","journal-title":"Neurol Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa588","article-title":"Smallpox","volume":"224","author":"Breman","year":"2021","journal-title":"J Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: Challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2013developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat Rev Drug Discovery"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3390\/vaccines9121490","article-title":"Vaccine technologies and platforms for infectious diseases: Current progress, challenges, and opportunities","volume":"9","author":"Ghattas","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2311","article-title":"Translational control by changes in poly(A) tail length: recycling mRNAs","volume":"19","author":"Weill","year":"2012","journal-title":"Nat Struct Mol Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.28851","article-title":"Eukaryotic initiation factor 4E (eIF4E): A recap of the cap-binding protein","volume":"120","author":"Batool","year":"2019","journal-title":"J Cell Biochem"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw551","article-title":"mRNA capping: biological functions and applications","volume":"44","author":"Ramanathan","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nature09489","article-title":"2\u2019-O methylation of the viral mRNA cap evades host restriction by IFIT family members","volume":"468","author":"Daffis","year":"2010","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.tcb.2018.11.002","article-title":"Tales of detailed Poly(A) tails","volume":"29","author":"Nicholson","year":"2019","journal-title":"Trends Cell Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.10.7.3441-3455.1990","article-title":"mRNA poly(A) tail, a 3\u2019 enhancer of translational initiation","volume":"10","author":"Munroe","year":"1990","journal-title":"Mol Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.3499","article-title":"Short poly(A) tails are a conserved feature of highly expressed genes","volume":"24","author":"Lima","year":"2017","journal-title":"Nat Struct Mol Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1086\/319857","article-title":"Self-replicative RNA vaccines elicit protection against influenza a virus, respiratory syncytial virus, and a tickborne encephalitis virus","volume":"183","author":"Fleeton","year":"2001","journal-title":"J Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.omtm.2018.10.010","article-title":"Efficient induction of T cells against conserved HIV-1 regions by mosaic vaccines delivered as self-amplifying mRNA","volume":"12","author":"Moyo","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00113-4","article-title":"Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus","volume":"19","author":"Pushko","year":"2000","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2017.08.019","article-title":"Immunogenicity of virus-like semliki forest virus replicon particles expressing Indian HIV-1C gag, env and polRT genes","volume":"190","author":"Ajbani","year":"2017","journal-title":"Immunol Lett"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.07.048","article-title":"A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge","volume":"25","author":"Greer","year":"2007","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/vaccines9020097","article-title":"An update on self-amplifying mRNA vaccine development","volume":"9","author":"Blakney","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.896958","article-title":"Recent advances in the molecular design and delivery technology of mRNA for vaccination against infectious diseases","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.02.036","article-title":"A role for codon order in translation dynamics","volume":"141","author":"Cannarozzi","year":"2010","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40259-018-0261-x","article-title":"Codon optimization in the production of recombinant biotherapeutics: Potential risks and considerations","volume":"32","author":"Mauro","year":"2018","journal-title":"BioDrugs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center b cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-00042-z","article-title":"Trial settles debate over best design for mRNA in COVID vaccines","volume":"613","author":"Dolgin","year":"2023","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/vaccines8010123","article-title":"mRNA vaccines encoding the HA protein of influenza a H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice","volume":"8","author":"Zhuang","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3390\/vaccines9070734","article-title":"Detailed dissection and critical evaluation of the Pfizer\/BioNTech and moderna mRNA vaccines","volume":"9","author":"Xia","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04231-6","article-title":"Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine","volume":"601","author":"Gebre","year":"2022","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A facile method for the removal of dsRNA contaminant from In vitro-transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/biomedicines10010050","article-title":"mRNA therapeutic modalities design, formulation and manufacturing under pharma 4.0 principles","volume":"10","author":"Ouranidis","year":"2021","journal-title":"Biomedicines"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discovery"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.16.6077","article-title":"Cationic liposome-mediated RNA transfection","volume":"86","author":"Malone","year":"1989","journal-title":"Proc Natl Acad Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2005.06.031","article-title":"Drastic effect of nanoapatite particles on liposome-mediated mRNA delivery to mammalian cells","volume":"345","author":"Zohra","year":"2005","journal-title":"Anal Biochem"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1039\/C8TX00005K","article-title":"Correlation of the cytotoxic effects of cationic lipids with their headgroups","volume":"7","author":"Cui","year":"2018","journal-title":"Toxicol Res (Camb)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.005","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes","volume":"354","author":"Ishida","year":"2008","journal-title":"Int J Pharm"},{"key":"B40","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3390\/pharmaceutics14020460","article-title":"The potential of nanomedicine to unlock the limitless applications of mRNA","volume":"14","author":"Taina-Gonz\u00e1lez","year":"2022","journal-title":"Pharmaceutics"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-020-00886-0","article-title":"Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-cas gene editing","volume":"20","author":"Liu","year":"2021","journal-title":"Nat Mater"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery","volume":"99","author":"Cheng","year":"2016","journal-title":"Adv Drug Delivery Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemphyslip.2016.05.003","article-title":"The role of cholesterol in membrane fusion","volume":"199","author":"Yang","year":"2016","journal-title":"Chem Phys Lipids"},{"key":"B45","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41467-020-14527-2","article-title":"Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA","volume":"11","author":"Patel","year":"2020","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc Chem Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5b03184","article-title":"Physical principles of nanoparticle cellular endocytosis","volume":"9","author":"Zhang","year":"2015","journal-title":"ACS Nano"},{"key":"B48","doi-asserted-by":"publisher","first-page":"102249","DOI":"10.1016\/j.coi.2022.102249","article-title":"Innate sensing of mRNA vaccines","volume":"79","author":"Wuebben","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.immuni.2020.03.009","article-title":"Immune sensing of synthetic, bacterial, and protozoan RNA by toll-like receptor 8 requires coordinated processing by RNase T2 and RNase 2","volume":"52","author":"Ostendorf","year":"2020","journal-title":"Immunity"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.cell.2019.11.001","article-title":"TLR8 is a sensor of RNase T2 degradation products","volume":"179","author":"Greulich","year":"2019","journal-title":"Cell"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2943","article-title":"Toll-like receptor 8 senses degradation products of single-stranded RNA","volume":"22","author":"Tanji","year":"2015","journal-title":"Nat Struct Mol Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.09.011","article-title":"Structural analysis reveals that toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA","volume":"45","author":"Zhang","year":"2016","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"B55","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1073\/pnas.1515152113","article-title":"Structural basis for m7G recognition and 2\u2019-o-methyl discrimination in capped RNAs by the innate immune receptor RIG-I","volume":"113","author":"Devarkar","year":"2016","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.immuni.2015.06.015","article-title":"A conserved histidine in the RNA sensor RIG-I controls immune tolerance to N1-2\u2019O-Methylated self RNA","volume":"43","author":"Schuberth-Wagner","year":"2015","journal-title":"Immunity"},{"key":"B57","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.virol.2015.01.019","article-title":"Innate immune restriction and antagonism of viral RNA lacking 2'-O methylation","author":"Hyde","year":"2015","journal-title":"Virology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1612444114","article-title":"Structure of human IFIT1 with capped RNA reveals adaptable mRNA binding and mechanisms for sensing N1 and N2 ribose 2\u2019-O methylations","volume":"114","author":"Abbas","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2016.02.001","article-title":"When your cap matters: structural insights into self vs non-self recognition of 5\u2019 RNA by immunomodulatory host proteins","volume":"36","author":"Leung","year":"2016","journal-title":"Curr Opin Struct Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ai.2016.11.001","article-title":"Nucleic acid immunity","volume":"133","author":"Hartmann","year":"2017","journal-title":"Adv Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring mRNA vaccine to balance Innate\/Adaptive immune response","volume":"26","author":"Linares-Fern\u00e1ndez","year":"2020","journal-title":"Trends Mol Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.714170","article-title":"Efficacy, immunogenicity and safety of COVID-19 vaccines: A systematic review and meta-analysis","volume":"12","author":"Sharif","year":"2021","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00677-0","article-title":"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial","volume":"22","author":"Kremsner","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/imr.12963","article-title":"Classical CD4 T cells as the cornerstone of antimycobacterial immunity","volume":"301","author":"Morgan","year":"2021","journal-title":"Immunol Rev"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301236","article-title":"Cutting edge: Direct recognition of infected cells by CD4 T cells is required for control of intracellular mycobacterium tuberculosis in vivo","volume":"191","author":"Srivastava","year":"2013","journal-title":"J Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200061","article-title":"IFN-\u03b3 from CD4 T cells is essential for host survival and enhances CD8 T cell function during mycobacterium tuberculosis infection","volume":"190","author":"Green","year":"2013","journal-title":"J Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006384","article-title":"MHC ib molecule qa-1 presents mycobacterium tuberculosis peptide antigens to CD8+ T cells and contributes to protection against infection","volume":"13","author":"Bian","year":"2017","journal-title":"PloS Pathog"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005688","article-title":"Nonclassical MHC ib-restricted CD8+ T cells recognize mycobacterium tuberculosis-derived protein antigens and contribute to protection against infection","volume":"12","author":"Shang","year":"2016","journal-title":"PloS Pathog"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-6111-1_8","article-title":"Antigen-specific CD8(+) T cells and protective immunity to tuberculosis","volume":"783","author":"Behar","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.10.6333","article-title":"T Cell responses are better correlates of vaccine protection in the elderly","volume":"176","author":"McElhaney","year":"2006","journal-title":"J Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00397-07","article-title":"Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children","volume":"15","author":"Forrest","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#","article-title":"In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies","volume":"30","author":"Hoerr","year":"2000","journal-title":"Eur J Immunol"},{"key":"B77","article-title":"Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization","volume":"3","author":"Qiu","year":"1996","journal-title":"Gene Ther"},{"key":"B78","article-title":"Characterization of a messenger RNA polynucleotide vaccine vector","volume":"55","author":"Conry","year":"1995","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.08.008","article-title":"SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic","volume":"55","author":"Bertoletti","year":"2022","journal-title":"Immunity"},{"key":"B80","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12985-022-01919-7","article-title":"An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs","volume":"19","author":"Li","year":"2022","journal-title":"Virol J"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","article-title":"Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination","volume":"54","author":"Painter","year":"2021","journal-title":"Immunity"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.08.006","article-title":"Efficient targeting and activation of antigen-presenting cells In vivo after modified mRNA vaccine administration in rhesus macaques","volume":"25","author":"Liang","year":"2017","journal-title":"Mol Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010255","article-title":"Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses","volume":"18","author":"Ndeupen","year":"2022","journal-title":"PloS Pathog"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04527-1","article-title":"Germinal centre-driven maturation of b cell response to mRNA vaccination","volume":"604","author":"Kim","year":"2022","journal-title":"Nature"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"B88","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2021.12.026","article-title":"SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans","volume":"185","author":"Mudd","year":"2022","journal-title":"Cell"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell"},{"key":"B91","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1126\/science.abj9853","article-title":"Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells","volume":"374","author":"Mateus","year":"2021","journal-title":"Sci (1979)"},{"key":"B92","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03841-4","article-title":"Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine","volume":"597","author":"Oberhardt","year":"2021","journal-title":"Nature"},{"key":"B95","doi-asserted-by":"publisher","first-page":"100355","DOI":"10.1016\/j.xcrm.2021.100355","article-title":"Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abj1750","article-title":"SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees","volume":"6","author":"Geers","year":"2021","journal-title":"Sci Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"B98","doi-asserted-by":"publisher","first-page":"188","DOI":"10.21203\/rs.3.rs-2199652\/v1","article-title":"Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals","volume":"6","author":"Connors","year":"2022","journal-title":"Res Sq"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14050973","article-title":"Ionizable lipid nanoparticles enhanced the synergistic adjuvant effect of CpG ODNs and QS21 in a varicella zoster virus glycoprotein e subunit vaccine","volume":"14","author":"Luan","year":"2022","journal-title":"Pharmaceutics"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.10.132","article-title":"A novel lipid nanoparticle adjuvant significantly enhances b cell and T cell responses to sub-unit vaccine antigens","volume":"34","author":"Swaminathan","year":"2016","journal-title":"Vaccine"},{"key":"B101","doi-asserted-by":"publisher","first-page":"34215","DOI":"10.1038\/srep34215","article-title":"A tetravalent Sub-unit dengue vaccine formulated with ionizable cationic lipid nanoparticle induces significant immune responses in rodents and non-human primates","volume":"6","author":"Swaminathan","year":"2016","journal-title":"Sci Rep"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0247-3","article-title":"Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation","volume":"37","author":"Miao","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.06.014","article-title":"Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines","volume":"27","author":"Hartikka","year":"2009","journal-title":"Vaccine"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2013.12.003","article-title":"Cationic lipid nanocarriers activate toll-like receptor 2 and NLRP3 inflammasome pathways","volume":"10","author":"Lonez","year":"2014","journal-title":"Nanomedicine"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737998","article-title":"DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through toll-like receptor 4","volume":"38","author":"Tanaka","year":"2008","journal-title":"Eur J Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytesin vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur J Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.3390\/ijms21145130","article-title":"Self-amplifying RNA viruses as RNA vaccines","volume":"21","author":"Lundstrom","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2000.0635","article-title":"Influenza virus (A\/HK\/156\/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses","volume":"278","author":"Schultz-Cherry","year":"2000","journal-title":"Virology"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2436","article-title":"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza a virus infection","volume":"30","author":"Petsch","year":"2012","journal-title":"Nat Biotechnol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.8.3791-3799.2002","article-title":"Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity","volume":"76","author":"Anraku","year":"2002","journal-title":"J Virol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.24.15107-15113.2005","article-title":"Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus","volume":"79","author":"Aberle","year":"2005","journal-title":"J Virol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1997.13.1487","article-title":"Outcome of immunization of cynomolgus monkeys with recombinant semliki forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus","volume":"13","author":"Berglund","year":"1997","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.11.7135-7145.2005","article-title":"Characterization of human immunodeficiency virus gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles","volume":"79","author":"Gupta","year":"2005","journal-title":"J Virol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.8.4598","article-title":"Stable alphavirus packaging cell lines for sindbis virus and semliki forest virus-derived vectors","volume":"96","author":"Polo","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv019","article-title":"A kunjin replicon virus-like particle vaccine provides protection against Ebola virus infection in nonhuman primates","author":"Pyankov","year":"2015","journal-title":"J Infect Dis"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol Ther"},{"key":"B119","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41541-021-00420-6","article-title":"Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza","volume":"6","author":"Chivukula","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2206333119","article-title":"Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses","volume":"119","author":"McMahon","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"B121","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Sci (1979)"},{"key":"B122","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1038\/s41467-022-32149-8","article-title":"Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza b viruses","volume":"13","author":"Pardi","year":"2022","journal-title":"Nat Commun"},{"key":"B123","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41541-020-0163-z","article-title":"Modified mRNA\/lipid nanoparticle-based vaccines expressing respiratory syncytial virus f protein variants are immunogenic and protective in rodent models of RSV infection","volume":"5","author":"Espeseth","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004746","article-title":"An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs","volume":"10","author":"Schnee","year":"2016","journal-title":"PloS Negl Trop Dis"},{"key":"B125","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41541-022-00577-8","article-title":"mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of plasmodium falciparum","volume":"7","author":"Hayashi","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B126","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.omtn.2019.03.003","article-title":"Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques","volume":"15","author":"Pardi","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01574-5","article-title":"A multiclade env\u2013gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques","volume":"27","author":"Zhang","year":"2021","journal-title":"Nat Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.945706","article-title":"Comparative immunogenicity of an mRNA\/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques","volume":"13","author":"Valentin","year":"2022","journal-title":"Front Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and toxoplasma gondii challenges with a single dose","volume":"113","author":"Chahal","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"key":"B131","doi-asserted-by":"publisher","first-page":"16076","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis","volume":"2","author":"Pai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B132","volume-title":"Global tuberculosis report 2022","year":"2022"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.21.0372","article-title":"The 100 th anniversary of bacille calmette-gu\u00e9rin (BCG) and the latest vaccines against COVID-19","volume":"25","author":"Bettencourt","year":"2021","journal-title":"Int J Tuberculosis Lung Dis"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.11.038","article-title":"100 years of the bacillus calmette-gu\u00e9rin vaccine","volume":"39","author":"Bettencourt","year":"2021","journal-title":"Vaccine"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.02.010","article-title":"Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells","volume":"29","author":"Derrick","year":"2011","journal-title":"Vaccine"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/nri2274","article-title":"T-Cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3390\/vaccines8040586","article-title":"An overview of the development of new vaccines for tuberculosis","volume":"8","author":"Whitlow","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1935328","article-title":"Where are the RNA vaccines for TB","volume":"10","author":"Fan","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00014-18","article-title":"Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine","volume":"86","author":"Stylianou","year":"2018","journal-title":"Infect Immun"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41541-019-0148-y","article-title":"Identification of antigens presented by MHC for vaccines against tuberculosis","volume":"5","author":"Bettencourt","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B141","doi-asserted-by":"publisher","first-page":"13836","DOI":"10.1038\/s41598-021-93266-w","article-title":"An immunoinformatics approach to design a multi-epitope vaccine against mycobacterium tuberculosis exploiting secreted exosome proteins","volume":"11","author":"Sharma","year":"2021","journal-title":"Sci Rep"},{"key":"B142","doi-asserted-by":"publisher","first-page":"4645","DOI":"10.1038\/s41598-022-08506-4","article-title":"Novel in silico mRNA vaccine design exploiting proteins of m. tuberculosis that modulates host immune responses by inducing epigenetic modifications","volume":"12","author":"al Tbeishat","year":"2022","journal-title":"Sci Rep"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-022-10515-4","article-title":"Modeling of MT. P495, an mRNA-based vaccine against the phosphate-binding protein PstS1 of mycobacterium tuberculosis","author":"Shahrear","year":"2022","journal-title":"Mol Divers"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.11.6324-6329.2004","article-title":"RNA Encoding the MPT83 antigen induces protective immune responses against mycobacterium tuberculosis infection","volume":"72","author":"Xue","year":"2004","journal-title":"Infect Immun"},{"key":"B145","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1472-6750-10-77","article-title":"Intranasal vaccination with messenger RNA as a new approach in gene therapy: Use against tuberculosis","volume":"10","author":"Lorenzi","year":"2010","journal-title":"BMC Biotechnol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/vaccines11010130","article-title":"An RNA-based vaccine platform for use against mycobacterium tuberculosis","volume":"11","author":"Larsen","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B147","doi-asserted-by":"publisher","first-page":"102302","DOI":"10.1016\/j.tube.2022.102302","article-title":"Immunogenicity and protection against mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen","volume":"138","author":"Rais","year":"2023","journal-title":"Tuberculosis"},{"key":"B148","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/vaccines9020134","article-title":"HIV mRNA vaccines\u2013progress and future paths","volume":"9","author":"Mu","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1208","article-title":"HIV \/ AIDS vaccines: 2018","volume":"104","author":"Robinson","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan0662","article-title":"Developing an HIV vaccine","volume":"355","author":"Haynes","year":"2017","journal-title":"Sci (1979)"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12075","article-title":"HIV-1 neutralizing antibodies: understanding nature\u2019s pathways","volume":"254","author":"Mascola","year":"2013","journal-title":"Immunol Rev"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1129905","article-title":"HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies","volume":"15","author":"Sliepen","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663919","article-title":"Anti-HIV-1 ADCC and HIV-1 env can be partners in reducing latent HIV reservoir","volume":"12","author":"Suryawanshi","year":"2021","journal-title":"Front Immunol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12977-018-0435-0","article-title":"Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design","volume":"15","author":"Finney","year":"2018","journal-title":"Retrovirology"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2014.861748","article-title":"Novel approaches in polyepitope T-cell vaccine development against HIV-1","volume":"13","author":"Karpenko","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"B156","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41541-021-00307-6","article-title":"Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates","volume":"6","author":"Saunders","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-021-00982-0","article-title":"Malaria vaccine roller coaster","volume":"6","author":"Nkumama","year":"2021","journal-title":"Nat Microbiol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1038\/216160a0","article-title":"Protective immunity produced by the injection of X-irradiated sporozoites of plasmodium berghei","volume":"216","author":"Nussenzweig","year":"1967","journal-title":"Nature"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1126\/science.1241800","article-title":"Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine","volume":"341","author":"Seder","year":"2013","journal-title":"Sci (1979)"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1126\/science.1211548","article-title":"Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity","volume":"334","author":"Epstein","year":"2011","journal-title":"Sci (1979)"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01470-y","article-title":"Safety, immunogenicity and efficacy of PfSPZ vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"27","author":"Oneko","year":"2021","journal-title":"Nat Med"},{"key":"B162","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","article-title":"Safety and efficacy of PfSPZ vaccine against plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial","volume":"17","author":"Sissoko","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1882309","article-title":"Correlates of malaria vaccine efficacy","volume":"20","author":"Stanisic","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1172\/JCI156588","article-title":"RTS,S: the first malaria vaccine","volume":"132","author":"Zavala","year":"2022","journal-title":"J Clin Invest"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant matrix-m, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00523-0","article-title":"Next-generation malaria subunit vaccines to reduce disease burden in African children","volume":"22","author":"Daubenberger","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-m vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B168","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41541-021-00345-0","article-title":"Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice","volume":"6","author":"Mallory","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2220-1","article-title":"Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria","volume":"582","author":"Raj","year":"2020","journal-title":"Nature"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1026052","article-title":"Exploring in vitro expression and immune potency in mice using mRNA encoding the plasmodium falciparum malaria antigen, CelTOS","volume":"13","author":"Waghela","year":"2022","journal-title":"Front Immunol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"310ra167","DOI":"10.1126\/scitranslmed.aac5477","article-title":"Identification of broadly conserved cross-species protective leishmania antigen and its responding CD4 + T cells","volume":"7","author":"Mou","year":"2015","journal-title":"Sci Transl Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1172691\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T04:27:12Z","timestamp":1682310432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1172691\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":171,"alternative-id":["10.3389\/fimmu.2023.1172691"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1172691","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"article-number":"1172691"}}